A clinical trial update was recorded on September 10, 2026, for a study titled "Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma." The trial, registered as NCT07812467, is listed in Phase 2.
According to the registration record, the study status is "not yet recruiting." This means participant enrollment has not begun as of the date reported.
The trial is designed to evaluate a neoadjuvant chemoimmunotherapy approach sensitized with rimegepant in patients with oral or oropharyngeal squamous cell carcinoma, based on the study title. No additional details on eligibility, outcomes, or timelines are included in this update.
No results, efficacy data, or safety findings have been reported for this trial at this stage, since recruitment has not started. Further updates would be expected once the trial status changes, such as when recruitment opens or results become available.
Readers interested in background information on calcitonin can consult the compound overview for additional context.